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Summana The relationship between intrauterine device (IUD) use and risk of endometrial cancer has been
analysed in a case-control study conducted in Italy between 1983 and 1992. including 453 patients with
histologicallv confirmed endometrial cancer and 1.451 controls admitted for acute. non-gvnaecological. non-
hormonal. non-neoplastic conditions to the same network of hospitals where cases had been identified. Two
(0.40o) cases versus 36 (2.3%) controls reported ever using an IUD. The corresponding multivariate relative
risk was 0.4 (9500 Cl 0.1-1.0). The results of this study and the few published available epidemiological data
suggest a protective role of IUD use on endometrial carcinogenesis. but potential selective mechanisms for
IUD utilisation (indication bias) should be carefully considered in the interpretation.
Intrauterine device (IUD) use may induce endometrial altera-
tions. such as inflammatory changes (Sheppard, 1987). loss of
epithelial surface (El-Badrawi et al.. 1981) and reduction in
ciliated cells (Gonzalez-Angulo et al.. 1973). which may affect
the risk of neoplastic changes of the endometnrum. In terms
of biological inference. the risk of endometrial cancer might
be either increased or decreased by such changes.
Epidemiological data on the relation between IUD use and
risk of endometrial cancer are, however, scanty. A recent
analysis of data from the Cancer and Steroid Hormones
(CASH) Study suggested that the risk of endometnral cancer
is approximately halved in women reporting ever IUD use.
and the protective effect tended to increase with duration of
use (Castellsague et al.. 1993). To offer further data on the
issue. we report the results from a case-control study con-
ducted in Northern Italy (Parazzini et al.. 1991a).
Patients and methods
The general design of this study has been previously de-
scribed (Parazzini et al.. 1991a). Cases included in the study
were 453 patients with histologically confirmed endometrial
cancer aged <65 years (median age 56 years. range 28-64).
They were admitted to the Ospedale Maggiore (including the
four largest teaching and general hospitals in the greater
Milan area). to the University Obstetrics and Gynecology
Clinics and to the National Cancer Institute of Milan
between 1983 and 1992. They were interviewed during their
stay in hospital for surgery. medical treatment, radiotherapy:
their diagnosis of endometrial cancer dated back no more
than 1 year (median time from diagnosis to interview 2
months. range 0-12 months).
Controls were patients younger than 65 years admitted for
acute. non-gynaecological. non-hormone-related. non-
neoplastic conditions to the same network of hospitals where
cases had been identified. Women who had undergone hys-
terectomy were not eligible as controls. A total of 1,541
controls (median age 53 years. range 27-64) was included in
the present analy ses. Of these. 32% were admitted for
traumatic conditions (mostly fractures and sprains), 35% had
non-traumatic orthopaedic disorders (mostly low back pain
and disc disorders). 15% had surgical conditions (mostly
abdominal, such as acute appendicitis or strangulated hernia)
and 18% had other illnesses. such as ear. nose and throat or
dental disorders. Less than 3% of identified cases and con-
trols refused to be interviewed.
Trained interviewers identified and questioned cases and
controls using a standard questionnaire. Information was
collected on general characteristics and habits. gynaecological
and obstetric data. related medical historv and use of oral
contraceptives. intrauterine devices (IUD) and female hor-
mones for other indications.
Odds ratios. as estimators of relative risks (RR) of endo-
metrial cancer, together with their 95% confidence intervals
(CI), according to use of IUD were computed from data
stratified for quinquennia of age by the Mantel-Haenszel
procedure (Mantel & Haenszel. 1959). In order to allow
simultaneously for the effects of several potential confound-
ing factors. unconditional multiple logistic regression. with
maximum likelihood fitting. was used (Breslow & Day. 1980).
Included in the regression equations were terms for age and
selected factors significantly associated in this data set with
the risk of endometrial cancer (parity. Quetelet's index and
oestrogen replacement therapy use).
Results
The distribution of cases and controls according to age and
selected covanrates is presented in Table I. Cases were more
frequently nulliparae (RR age adjusted. parae versus null-
parae. 0.6: 95% CI 0.4-0.9). of higher body mass index (age
adjusted RR. kg m-- > 25 *s <25. 2.0: 95%0CI 1.7-2.4)
and more often oestrogen replacement therapy users (RR
ever versus never 2.0. 95% CI 1.3-3.1).
The relation between IUD use and endometrial cancer risk
is considered in Table II. Out of the 453 endometrial cancer
cases. two (0.4%) reported ever having used an IUD: the
figures for controls were 36 ever users (2.30 o) out of the
1.541 controls. The corresponding RR of endometrial cancer
was, in comparison with never users. 0.4 (95% CI 0.1 - 1.0)
for ever IUD users. The data were insufficient for analysis of
duration of use or other time-related factors.
Discussion
The results of this analysis further suggest that IUD use
reduces the risk of endometrial cancer, but the interpretation
deserves caution. In fact. indication bias may. at least par-
tially, explain this inverse association. IUD may be less
frequently prescribed in women with long, heavy menstrual
flows or reporting pre-. post- or inter-menstrual blood spot-
ting. conditions that may be associated with unopposed oest-
rogen endometrial stimulation and consequently increased
endometrial cancer risk. Another potential limitation of this
study is the low number of IUD users in Italy. which did not
provide the opportunity to analyse the role of duration and
any other time-related factors. In relation to other potential
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Table I Distribution of 453 endometrial cancer cases and 1,541
controls according to selected characteristics, Milan, Italy.
1983-1992
Cases Controls
NO. (% No. !'o
Age (years)
<45 37 (8.2) 188 (12.2)
45-54 145 (32.0) 690 (44.8)
55-64 271 (59.8) 663 (43.0)
Education (years)
<7 300 (66.2) 925 (60.0)
7-11 94 (20.8) 372 (24.1)
E1, 59 (13.0) 244 (15.8)
No. of births
0 101 (22.3) 273 (17.7)
1 -2 244 (53.9) 875 (56.8)
>' 3 108 (23.8) 393 (25.5)
Quetelet's index (kg m-
<25 197 (43.5) 898 (58.3)
25-30 147 (32.5) 478 (31.0)
>30 109 (24.1) 165 (10.7)
Oral contraceptive use
Never 431 (95.1) 1436 (93.2)
Ever '2 (4.9) 105 (6.8)
Oestrogen replacement therapy
Never 408 (90.1) 1468 (95.3)
Ever 45 (9.9) 73 (4.7)
Table 11 Distribution of 453 endometrial cancer cases and 1.541
controls according to indicators of IUD use. Milan. Italy 1983-1992
Relative risk
(95% confidence interval)
ILD use Endometrial cancer Controls .1IHf ML `
Never 451 1505 Ic 1'
Ever 2 36 0.2 (0.1-0.9) 0.4 (0.1-1.0)
-Adjusted for age by the Mantel-Haenszel procedure. bMultiple
logistic regression including terms for age. parity. body mass index and
oestrogen replacement therapy. cReference categorv.
biases. cases and controls were identified in institutions
covering broadly comparable catchment areas, and participa-
tion was almost complete. Likewise. recall bias is unlikely.
since the interviewed cases and controls and the interviewers
were unaware of the potential association between IUD use
and endometrial cancer risk.
We did not have information on type of IUD used, thus
we cannot evaluate the role of different types of IUD. parti-
cularly progestin-releasing ones. Despite these considerations,
some biological evidence, the consistency of our results with
data from the CASH study (Castellsague et al., 1993) and the
magnitude of the association offer some support to the hypo-
thesis that IUD use reduces the risk of endometrial cancer.
The CASH study showed a decreased risk of endometrial
cancer in IUD users of about 50%; in that study the risk
tended to decrease with duration of use. offering some sup-
port to the hypothesis of a causal relationship, although the
trend in risk with duration was not significant (Castellsague
et al., 1993).
In biological terms, laboratory and animal studies have
suggested that IUD use may alter the response to steroids of
the endometrium. These changes are mediated by the device
itself as well as by the copper ions present in some devices.
These alterations inhibit binding of oestrogen and pro-
gesterone to the endometrial cell receptors (Tamaya et al..
1976) and decrease the steroid nuclear receptor concentration
in the endometrial cells (Myatt et al., 1980). These changes,
however, may influence both oestrogen and progesterone
activity, which have opposing effects on endometrial car-
cinogenesis (Parazzini et al., 1991b).
In conclusion, the few available epidemiological data sug-
gest a protective effect of IUD use on endometrial cancer
risk, but potential indication or selection bias is difficult to
overcome in any epidemiological study on the issue. and
should therefore be carefully considered in the interpreta-
tion.
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